Cogent Biosciences
COGT
28 hedge funds and large institutions have $186M invested in Cogent Biosciences in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
22.23% more ownership
Funds ownership: 0% → 22.23% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
+$37.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.8M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$12.6M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$12M |
| 5 |
Jennison Associates
New York
|
+$9.96M |
Top Sellers
COGT Hedge Fund Activity: Q1 2018 in Review
28 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2018, worth a combined $186M.
Buyers outnumbered sellers: 28 funds opened new COGT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Atlas Venture Associates IX, opening a new position worth an estimated $37.3M.
- 28 institutional investors held Cogent Biosciences (COGT) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $186M of Cogent Biosciences stock for Q1 2018.
- 28 funds opened new Cogent Biosciences positions in Q1 2018 and 0 closed out, a net change of +28 holders.
- The largest Cogent Biosciences buyer in Q1 2018 was Atlas Venture Associates IX, an estimated $37.3M added.
Based on aggregated 13F filings for Q1 2018.